c. 5,545,405 ("'405"), which issued on 13 August 1996 from application
08/335,401, filed 3 November 1994.
2. Glaxo is said to be the assignee of the three patents (Paper 9).
3. Martin J. Page and James Scott Crowe are said to be coinventors of the subject
matter claimed in the ‘403, '404 and '405 patents (Paper 46).1
The senior party
4. Cabilly is involved in the interference on the basis of its 08/909,611 ("'611")
application which was filed 12 August 1997.
5. Genentech, Inc. is said to be the assignee of the '611 application (Paper 5).
6. Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, and
Ronald B. Wetzel are said to be coinventors of the subject matter claimed in the '611 application.
The count
7. The sole count of the interference, Count 1, is as follows (Paper 1 at 49):
A method according to claim 1 of 5,545,403
or
a method according to claim 1 of 5,545,404
or
a method according to claim 1 of 5,545,405
or
a method according to any of claims 53, 55, or 56 of 08/909,611.
8. Claim 1 of the '403 patent reads as follows:
1 Glaxo points out that the Notice Declaring Interference (Paper 1) did not list
James Scott Crowe as an inventor as to the ‘403 patent (Paper 46).
-4-
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007